HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

PEGBIO CO-B

5.875

-0.100-1.67%

Volume:4.99M

Turnover:29.58M

Market Cap:2.30B

PE:-10.68

High:6.040

Open:5.990

Low:5.870

Close:5.975

52wk High:77.000

52wk Low:4.940

Shares:391.00M

HK Float Shares:386.00M

Volume Ratio:0.36

T/O Rate:1.29%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.550

ROE:-82.42%

ROA:-31.46%

PB:4.39

PE(LYR):-10.68

PS:-508.17

Loading ...

Overview Company News Filings

BRIEF-PegBio Enters Exclusive Commercialization Collaboration With Tenry Pharmaceutical For Paidakang In Mainland China

PEGBIO CO-B (02565) Enters Exclusive Commercialization Pact with Tengrui Pharma for Paidakang in Mainland China, Targeting Over RMB 10 Billion in Cumulative Sales and Receiving Approximately HK$140 Million in Rights Payment

PegBio signs exclusive Paidakang commercialization deal with Tenry Pharmaceutical worth HKD140 million

Pegbio Co Ltd - Aggregate Commercialization Sales Target Over RMB10 Bln, Royalty About HK$140 Mln

THOMSON REUTERS

Pegbio Co Ltd - Enters Exclusive Commercialization Collaboration With Tenry Pharmaceutical for Paidakang in Mainland China

THOMSON REUTERS

Dual Boost from Policy and R&D! Huabao Fund's Hong Kong Stock Connect Innovative Drug ETF (520880) Rises Over 1%, Led by Biocytogen-B and PegBio Co-B

PEGBIO CO-B (02565) Schedules 23 Mar 2026 Board Meeting to Approve FY 2025 Results

Bulletin Express

PegBio schedules board meeting to approve 2025 annual results

Revised Title

PegBio's GLP-1 Candidate Completes First-in-Human Dosing

MT Newswires Live

PEGBIO CO-B (02565) Announces Completion of CR059 First-in-Human Trial with One-Month Clinical Observations

Bulletin Express

PEGBIO CO-B (02565) Reports One-Month Clinical Data from First-in-Human Trial of Next-Generation GLP-1 Candidate CR059

PegBio Completes First-in-Human Single-Dose Trial of CR059 With Four-Week Observations Obtained

PEGBIO CO-B (02565) Enters Stock Connect: Can This GLP-1 Leader Challenge Eli Lilly's Global Dominance?

PEGBIO CO-B (02565) Announces February 2026 Equity Update

Bulletin Express

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/02565/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02565","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02565\",,,,,undefined,":{"symbol":"02565","market":"HK","secType":"STK","nameCN":"PEGBIO CO-B","latestPrice":5.875,"timestamp":1787299688008,"preClose":5.975,"halted":0,"volume":4987250,"delay":0,"changeRate":-0.01673640167364011,"floatShares":386000000,"shares":391000000,"eps":-0.55,"marketStatus":"Not Yet Opened","change":-0.1,"latestTime":"08-21 16:08:08","open":5.99,"high":6.04,"low":5.87,"amount":29583125,"amplitude":0.028452,"askPrice":5.9,"askSize":600,"bidPrice":5.875,"bidSize":23100,"shortable":3,"etf":0,"ttmEps":-0.612785,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":0,"adr":0,"listingDate":1748275200000,"exchange":"SEHK","adjPreClose":5.975,"openAndCloseTimeList":[[1787275800000,1787284800000],[1787288400000,1787299200000]],"volumeRatio":0.35780179890285707,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02565\",,,,,undefined,":{"symbol":"02565","floatShares":386000000,"roa":"-31.46%","roe":"-82.42%","lyrEps":-0.55,"volumeRatio":0.35780179890285707,"shares":391000000,"dividePrice":0,"high":6.04,"amplitude":0.028452,"preClose":5.975,"low":5.87,"week52Low":4.94,"pbRate":"4.39","psRate":"-508.17","week52High":77,"institutionHeld":0,"latestPrice":5.875,"committee":0.949367,"eps":-0.55,"divideRate":0,"volume":4987250,"delay":0,"ttmEps":-0.612785,"open":5.99,"prevYearClose":69,"prevWeekClose":5.875,"prevMonthClose":5.36,"prevQuarterClose":5.33,"fiveDayClose":6.23,"twentyDayClose":6.39,"sixtyDayClose":8.82,"earningDate":1787587200000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02565\",params:#limit:5,,,undefined,":[{"date":"2026-08-25","symbol":"02565","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787621400000,"name":null,"time":"","dateTimestamp":1787587200000,"actualEps":null},{"market":"HK","date":"2026-03-23","symbol":"02565","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774195200000,"reportTimeType":"post","actualEps":null},{"date":"2025-08-26","symbol":"02565","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756171800000,"name":null,"time":"","dateTimestamp":1756137600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02565\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02565\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02565\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02565","date":"2026-08-21","current":-9.587376,"percent":0.935811,"low":-87.782868,"twenty":-72.846173,"median":-58.454271,"eighty":-11.546541,"high":-7.824338,"avg":-44.305288,"sd":28.056716,"marketCap":2297662750},"quantilePoints":[{"date":"2025-05-30","current":-12.743079,"twenty":-15.470266,"median":-13.542645,"eighty":-13.135794,"marketCap":3936746426},{"date":"2025-06-06","current":-11.987888,"twenty":-13.726785,"median":-12.740515,"eighty":-12.114178,"marketCap":3712892217},{"date":"2025-06-13","current":-11.23576,"twenty":-13.295707,"median":-12.114337,"eighty":-11.528404,"marketCap":3481318898},{"date":"2025-06-20","current":-11.30775,"twenty":-12.841258,"median":-11.963331,"eighty":-11.337793,"marketCap":3496757119},{"date":"2025-06-27","current":-12.421214,"twenty":-12.738977,"median":-11.541778,"eighty":-11.292079,"marketCap":3851836209},{"date":"2025-07-04","current":-13.963875,"twenty":-12.971799,"median":-11.987888,"eighty":-11.299391,"marketCap":4330421069},{"date":"2025-07-11","current":-13.604213,"twenty":-13.050401,"median":-12.199189,"eighty":-11.305737,"marketCap":4214634409},{"date":"2025-07-18","current":-16.956264,"twenty":-13.748078,"median":-12.438987,"eighty":-11.330282,"marketCap":5248995235},{"date":"2025-07-25","current":-19.006677,"twenty":-15.472199,"median":-12.742066,"eighty":-11.352726,"marketCap":5905119639},{"date":"2025-08-01","current":-19.199848,"twenty":-18.276271,"median":-12.906561,"eighty":-11.424474,"marketCap":5928276971},{"date":"2025-08-08","current":-20.51103,"twenty":-19.019895,"median":-13.05938,"eighty":-11.472546,"marketCap":6348968501},{"date":"2025-08-15","current":-39.959751,"twenty":-19.179784,"median":-13.542645,"eighty":-11.515029,"marketCap":12350577024},{"date":"2025-08-22","current":-41.864246,"twenty":-19.284777,"median":-13.964282,"eighty":-11.779976,"marketCap":12898633879},{"date":"2025-08-29","current":-41.44792,"twenty":-21.432837,"median":-14.946806,"eighty":-11.968242,"marketCap":10033166343},{"date":"2025-09-05","current":-50.678037,"twenty":-39.039264,"median":-17.018603,"eighty":-12.06328,"marketCap":12255314482},{"date":"2025-09-12","current":-58.538001,"twenty":-40.749762,"median":-18.438762,"eighty":-12.114019,"marketCap":14181548421},{"date":"2025-09-19","current":-57.311117,"twenty":-43.720929,"median":-18.952908,"eighty":-12.216159,"marketCap":13874467648},{"date":"2025-09-26","current":-63.587749,"twenty":-49.33228,"median":-19.070122,"eighty":-12.366345,"marketCap":15354038645},{"date":"2025-10-03","current":-60.149194,"twenty":-54.575673,"median":-19.16943,"eighty":-12.428323,"marketCap":14558420278},{"date":"2025-10-10","current":-60.121463,"twenty":-57.957283,"median":-19.199848,"eighty":-12.49878,"marketCap":14530503844},{"date":"2025-10-17","current":-60.168303,"twenty":-59.756564,"median":-19.2984,"eighty":-12.738571,"marketCap":14530503844},{"date":"2025-10-24","current":-61.301982,"twenty":-60.143648,"median":-20.51103,"eighty":-12.741458,"marketCap":14809668183},{"date":"2025-10-31","current":-69.345185,"twenty":-60.159469,"median":-22.018639,"eighty":-12.743079,"marketCap":16777776773},{"date":"2025-11-07","current":-59.401661,"twenty":-60.392128,"median":-34.33922,"eighty":-12.780248,"marketCap":14363005241},{"date":"2025-11-14","current":-72.819022,"twenty":-61.035505,"median":-39.959751,"eighty":-12.906561,"marketCap":17657144441},{"date":"2025-11-21","current":-72.852961,"twenty":-61.301982,"median":-40.866122,"eighty":-12.943343,"marketCap":17657144441},{"date":"2025-11-28","current":-82.344376,"twenty":-62.346137,"median":-42.423494,"eighty":-13.014482,"marketCap":20030041323},{"date":"2025-12-05","current":-72.063717,"twenty":-63.355663,"median":-45.122001,"eighty":-13.104279,"marketCap":17559436923},{"date":"2025-12-12","current":-74.217813,"twenty":-64.460997,"median":-48.969529,"eighty":-13.233973,"marketCap":18117765601},{"date":"2025-12-19","current":-71.875632,"twenty":-65.413889,"median":-52.055133,"eighty":-13.542645,"marketCap":17587353357},{"date":"2025-12-24","current":-73.927127,"twenty":-69.382811,"median":-55.337969,"eighty":-13.579586,"marketCap":18145682035},{"date":"2026-01-02","current":-79.895405,"twenty":-70.540926,"median":-57.311117,"eighty":-13.748078,"marketCap":19687798475},{"date":"2026-01-09","current":-85.854057,"twenty":-72.056904,"median":-58.941314,"eighty":-13.964201,"marketCap":21208805289},{"date":"2026-01-16","current":-80.413876,"twenty":-72.839385,"median":-59.401661,"eighty":-14.164153,"marketCap":19929453763},{"date":"2026-01-23","current":-77.735339,"twenty":-73.262106,"median":-59.808211,"eighty":-14.656731,"marketCap":19247132950},{"date":"2026-01-30","current":-73.838267,"twenty":-73.550435,"median":-60.0941,"eighty":-15.472199,"marketCap":18365801899},{"date":"2026-02-06","current":-69.490034,"twenty":-73.32273,"median":-60.154331,"eighty":-16.538679,"marketCap":17328105662},{"date":"2026-02-13","current":-71.473742,"twenty":-73.562339,"median":-60.192909,"eighty":-17.006135,"marketCap":17925136373},{"date":"2026-02-20","current":-71.065981,"twenty":-73.716985,"median":-60.392128,"eighty":-17.056006,"marketCap":17797201221},{"date":"2026-02-27","current":-72.540901,"twenty":-73.438012,"median":-60.796223,"eighty":-17.950543,"marketCap":18365801899},{"date":"2026-03-06","current":-68.036226,"twenty":-73.352041,"median":-61.160082,"eighty":-18.384598,"marketCap":17086450373},{"date":"2026-03-13","current":-60.794114,"twenty":-73.299371,"median":-60.919795,"eighty":-18.597951,"marketCap":15338003289},{"date":"2026-03-20","current":-67.303035,"twenty":-73.275932,"median":-61.206433,"eighty":-18.84686,"marketCap":16915870170},{"date":"2026-03-27","current":-68.867925,"twenty":-73.269478,"median":-61.274827,"eighty":-18.985169,"marketCap":16247764373},{"date":"2026-04-02","current":-85.055535,"twenty":-73.278872,"median":-61.433108,"eighty":-19.026504,"marketCap":20163286400},{"date":"2026-04-10","current":-78.454069,"twenty":-73.369897,"median":-61.662876,"eighty":-19.045802,"marketCap":18741784705},{"date":"2026-04-17","current":-76.94604,"twenty":-73.948705,"median":-62.45145,"eighty":-19.079188,"marketCap":18389252284},{"date":"2026-04-24","current":-60.4786,"twenty":-73.948705,"median":-62.528681,"eighty":-19.126247,"marketCap":14454535592},{"date":"2026-05-15","current":-17.642518,"twenty":-73.927127,"median":-62.346137,"eighty":-19.115451,"marketCap":4376314243},{"date":"2026-05-22","current":-20.448357,"twenty":-73.838267,"median":-61.433108,"eighty":-19.16943,"marketCap":5060724424},{"date":"2026-05-29","current":-13.590249,"twenty":-73.716985,"median":-61.274827,"eighty":-19.064042,"marketCap":3375119921},{"date":"2026-06-05","current":-12.579887,"twenty":-73.438012,"median":-61.206433,"eighty":-18.597951,"marketCap":3128732256},{"date":"2026-06-12","current":-11.565594,"twenty":-73.352041,"median":-60.919795,"eighty":-17.056006,"marketCap":2874522760},{"date":"2026-06-18","current":-9.622776,"twenty":-73.31105,"median":-60.791238,"eighty":-14.753422,"marketCap":2397391091},{"date":"2026-06-26","current":-7.824338,"twenty":-73.278872,"median":-60.512398,"eighty":-13.899973,"marketCap":1939813998},{"date":"2026-07-03","current":-8.984958,"twenty":-73.271235,"median":-60.431019,"eighty":-13.561687,"marketCap":2229221732},{"date":"2026-07-10","current":-11.252888,"twenty":-73.25947,"median":-60.210807,"eighty":-13.050401,"marketCap":2788482623},{"date":"2026-07-17","current":-10.458113,"twenty":-73.235067,"median":-60.159469,"eighty":-12.830773,"marketCap":2600758687},{"date":"2026-07-24","current":-10.046967,"twenty":-73.215248,"median":-60.107782,"eighty":-12.739192,"marketCap":2499074889},{"date":"2026-07-31","current":-8.411523,"twenty":-73.183292,"median":-59.862622,"eighty":-12.522041,"marketCap":2096250611},{"date":"2026-08-07","current":-10.298244,"twenty":-73.061453,"median":-59.675079,"eighty":-12.306772,"marketCap":2571426822},{"date":"2026-08-14","current":-9.745542,"twenty":-72.966779,"median":-59.367669,"eighty":-11.991332,"marketCap":2436500244},{"date":"2026-08-21","current":-9.169953,"twenty":-72.846173,"median":-58.454271,"eighty":-11.546541,"marketCap":2297662750}],"updateTime":1787511975215},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02565\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2619463298","title":"BRIEF-PegBio Enters Exclusive Commercialization Collaboration With Tenry Pharmaceutical For Paidakang In Mainland China","url":"https://stock-news.laohu8.com/highlight/detail?id=2619463298","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619463298?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:54","pubTimestamp":1773665640,"startTime":"0","endTime":"0","summary":"BRIEF-PegBio Enters Exclusive Commercialization Collaboration With Tenry Pharmaceutical For Paidakang In Mainland ChinaMarch 16  - PegBio Co Ltd 2565.HK:ENTERS EXCLUSIVE COMMERCIALIZATION COLLABORATION WITH TENRY PHARMACEUTICAL FOR PAIDAKANG IN MAINLAND CHINAAGGREGATE COMMERCIALIZATION SALES TARGET OVER RMB10 BILLION, ROYALTY ABOUT HK$140 MILLIONFurther company coverage: 2565.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nFWN4040GX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172606217","title":"PEGBIO CO-B (02565) Enters Exclusive Commercialization Pact with Tengrui Pharma for Paidakang in Mainland China, Targeting Over RMB 10 Billion in Cumulative Sales and Receiving Approximately HK$140 Million in Rights Payment","url":"https://stock-news.laohu8.com/highlight/detail?id=1172606217","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172606217?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:54","pubTimestamp":1773658483,"startTime":"0","endTime":"0","summary":"PEGBIO CO-B (02565) has announced the signing of a strategic cooperation agreement with Shanghai Tengrui Pharmaceutical Co., Ltd. for the commercialization of its core product, Paidakang, in Mainland...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK4585","BK4588","399441","01477","02565","XBI","161726","BK1161","BK4581","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619547714","title":"PegBio signs exclusive Paidakang commercialization deal with Tenry Pharmaceutical worth HKD140 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2619547714","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619547714?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:50","pubTimestamp":1773658231,"startTime":"0","endTime":"0","summary":"PegBio entered a strategic cooperation agreement with Tenry Pharmaceutical for the commercialization of Paidakang in mainland China. Under the arrangement, Tenry will handle exclusive commercialization and promotion activities for the product in mainland China. The companies set a cumulative sales target of more than CNY 10 billion for Paidakang under the commercialization plan. Tenry will pay PegBio royalties totaling about HKD 140 million, which are expected to be paid within the current year. Sales revenue for Paidakang in mainland China will be recognized by PegBio, while PegBio retains intellectual property and overseas market interests for the product.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pegbio Co. Ltd. published the o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL7S60br:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619547904","title":"Pegbio Co Ltd - Aggregate Commercialization Sales Target Over RMB10 Bln, Royalty About HK$140 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2619547904","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619547904?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:50","pubTimestamp":1773658225,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nFWN4040GX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619454200","title":"Pegbio Co Ltd - Enters Exclusive Commercialization Collaboration With Tenry Pharmaceutical for Paidakang in Mainland China","url":"https://stock-news.laohu8.com/highlight/detail?id=2619454200","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619454200?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:50","pubTimestamp":1773658225,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nFWN4040GX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121911076","title":"Dual Boost from Policy and R&D! Huabao Fund's Hong Kong Stock Connect Innovative Drug ETF (520880) Rises Over 1%, Led by Biocytogen-B and PegBio Co-B","url":"https://stock-news.laohu8.com/highlight/detail?id=1121911076","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121911076?lang=en_us&edition=fundamental","pubTime":"2026-03-12 10:11","pubTimestamp":1773281490,"startTime":"0","endTime":"0","summary":"On the morning of March 12, the Hong Kong Stock Connect Innovative Drug ETF (520880) showed steady performance during the trading session, with its on-market price currently up 1.23%. The fund's...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02315","399441","BK1161","161726","BK4581","520880","XBI","BK4585","688796","BK4588","02565","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149352945","title":"PEGBIO CO-B (02565) Schedules 23 Mar 2026 Board Meeting to Approve FY 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1149352945","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149352945?lang=en_us&edition=fundamental","pubTime":"2026-03-11 16:42","pubTimestamp":1773218569,"startTime":"0","endTime":"0","summary":"PEG Bio Co., Ltd. (PEGBIO CO-B, stock code 02565) announced that its board of directors will convene on 23 March 2026. The agenda includes reviewing and approving the Group’s audited annual results...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618912336","title":"PegBio schedules board meeting to approve 2025 annual results","url":"https://stock-news.laohu8.com/highlight/detail?id=2618912336","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618912336?lang=en_us&edition=fundamental","pubTime":"2026-03-11 16:30","pubTimestamp":1773217859,"startTime":"0","endTime":"0","summary":"PegBio’s board will meet on March 23, 2026 to consider and approve the group’s annual results for the year ended December 31, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pegbio Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 11, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL72pwYL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178409030","title":"Revised Title","url":"https://stock-news.laohu8.com/highlight/detail?id=1178409030","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178409030?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:58","pubTimestamp":1773140298,"startTime":"0","endTime":"0","summary":"PEGBIO CO-B (02565) has announced that the board lot size for its H shares, each with a par value of RMB 1.00, traded on the Main Board of The Stock Exchange of Hong Kong Limited will be adjusted....","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4585","BK1161","BK4581","BK4588","161726","02565","399441"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618151616","title":"PegBio's GLP-1 Candidate Completes First-in-Human Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2618151616","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618151616?lang=en_us&edition=fundamental","pubTime":"2026-03-09 10:54","pubTimestamp":1773024857,"startTime":"0","endTime":"0","summary":"PegBio  said its next-generation GLP-1 receptor agonist CR059 has completed single-dose administration in a first-in-human clinical trial and generated one-month clinical observations, according to a March 6 Hong Kong bourse filing.Shares of the biopharmaceutical company were down nearly 2% in Monday morning trade.The study is evaluating the safety, tolerability, and pharmacokinetic and pharmacodynamic characteristics of CR059 in patients with type 2 diabetes mellitus, the company said.Preliminary observations four weeks after a single dose showed improvements in glycated hemoglobin, fasting blood glucose, and overall glucose control, PegBio said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02565","BK4590","BK1161","GLP","BK4144"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142171906","title":"PEGBIO CO-B (02565) Announces Completion of CR059 First-in-Human Trial with One-Month Clinical Observations","url":"https://stock-news.laohu8.com/highlight/detail?id=1142171906","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142171906?lang=en_us&edition=fundamental","pubTime":"2026-03-06 17:23","pubTimestamp":1772789011,"startTime":"0","endTime":"0","summary":"PegBio Co., Ltd. (02565) announced that CR059, a next-generation GLP-1 receptor agonist developed with circular RNA protein replacement technology and an AI-assisted molecular design platform, has...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100684135","title":"PEGBIO CO-B (02565) Reports One-Month Clinical Data from First-in-Human Trial of Next-Generation GLP-1 Candidate CR059","url":"https://stock-news.laohu8.com/highlight/detail?id=1100684135","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100684135?lang=en_us&edition=fundamental","pubTime":"2026-03-06 17:12","pubTimestamp":1772788377,"startTime":"0","endTime":"0","summary":"PEGBIO CO-B (02565) announced that CR059, its novel GLP-1 receptor agonist developed using a circular RNA (CircRNA) protein replacement technology and an AI-assisted molecular design platform, has...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565","BK1161","BK4590","GLP","399441","LABU","BK4585","BK4144","161726","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617685964","title":"PegBio Completes First-in-Human Single-Dose Trial of CR059 With Four-Week Observations Obtained","url":"https://stock-news.laohu8.com/highlight/detail?id=2617685964","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617685964?lang=en_us&edition=fundamental","pubTime":"2026-03-06 17:01","pubTimestamp":1772787671,"startTime":"0","endTime":"0","summary":"PegBio Co., Ltd. said its next-generation GLP-1 receptor agonist candidate CR059, developed using circular RNA protein replacement technology and delivered via a lipid nanoparticle system, has completed single-dose administration in a first-in-human trial in subjects with type 2 diabetes and has obtained four-week clinical observations. The company reported that four weeks after a single dose, glycated hemoglobin  and fasting blood glucose continued to improve versus baseline, continuous glucose monitoring showed time in range  increased, and mean blood glucose decreased. In preclinical studies, PegBio reported that in db/db mice CR059 showed a clear dose-response and superior metabolic intervention effects versus semaglutide under head-to-head conditions. In a spontaneous type 2 diabetes rhesus monkey model, once-monthly subcutaneous dosing  significantly reduced fasting plasma glucose with effects persisting across the dosing interval, and HbA1c continued improving versus baseline un","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL3sLdxv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183117083","title":"PEGBIO CO-B (02565) Enters Stock Connect: Can This GLP-1 Leader Challenge Eli Lilly's Global Dominance?","url":"https://stock-news.laohu8.com/highlight/detail?id=1183117083","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183117083?lang=en_us&edition=fundamental","pubTime":"2026-03-06 08:46","pubTimestamp":1772757965,"startTime":"0","endTime":"0","summary":"The most anticipated list in the Hong Kong stock market at the beginning of 2026 has been released. Starting March 9, PEGBIO CO-B (02565) officially became a constituent of the Hong Kong Stock...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014914.USD","LU2089283258.USD","SG9999014880.SGD","IE0001KFT4U8.USD","BK4534","IE00B2B36J28.USD","LU0823434583.USD","LU2360106947.USD","LU1551013425.SGD","LU2106854487.HKD","LU1712237335.SGD","SG9999001176.USD","LU2168564065.EUR","IE00BKDWB100.SGD","LLYZ","LU2237443549.SGD","LU2237443622.USD","LU2237443895.HKD","LU2265009873.SGD","LU2271345857.HKD","LU0353189680.USD","LU0823434740.USD","LU0820561818.USD","LU2237438978.USD","ELIL","IE00BN29S564.USD","LLY","IE00B7KXQ091.USD","LU1232071149.USD","LU0683600562.USD","LU2237443978.SGD","LU0256863902.USD","LU0823416689.USD","LU0203201768.USD","BK4599","LU1983299246.USD","IE00BJJMRZ35.SGD","LU2361044865.SGD","LU0323591593.USD","LU1548497426.USD","LU0889565916.HKD","SG9999013999.USD","LU1623119135.USD","GB00BDT5M118.USD","SG9999018865.SGD","LU0109394709.USD","LU0466842654.USD","LU2750360997.AUD","LU2087625088.SGD","SGXZ81514606.USD","LU0097036916.USD","LU1127390331.HKD","LU0006306889.USD","LU0432979614.USD","LU2023250504.SGD","BK4581","LU0354030511.USD","LU1291159041.SGD","LU2089984988.USD","LLII","LU0786609619.USD","LU0238689110.USD","IE0005OL40V9.USD","LU2168564222.USD","IE00BK4W5M84.HKD","LU2112291526.USD","LU0158827781.USD","LU2264538146.SGD","LU0316494557.USD","LU2324357040.USD","LU0096364046.USD","LU1868837300.USD","SGXZ31699556.SGD","SGXZ51526630.SGD","LU2168563687.JPY","IE00B1BXHZ80.USD","LLYX","IE00BFTCPJ56.SGD","LU1868837136.USD","SG9999015952.SGD","LU0672654240.SGD","IE00B4JS1V06.HKD","LU1974910355.USD","BK4516","LU2361044949.HKD","LU2168564495.EUR","IE00BK4W5L77.USD","LU2237443382.USD","LU2237443465.HKD","LU2468319806.SGD","LU2896262040.SGD","LU2417539215.USD","LU0114720955.EUR","IE00BKPKM429.USD","LU1145028129.USD","LU2236285917.USD","LU0256863811.USD","ELIS","LU1057294990.SGD","LU2213496289.HKD","LU1093756168.USD","LU2491049909.HKD","LU2023251221.USD","LU1917777945.USD","LU2750360641.GBP","LU1720051108.HKD","LU2491050071.SGD","LU1280957306.USD","LU2552382215.SGD","LU1035775433.USD","LU2108987350.USD","LU2462157665.USD","LU0820562030.AUD","LU0094547139.USD","LU1267930730.SGD","LU0471298694.HKD","LU1023059063.AUD","LU0689472784.USD","LU2471134796.USD","LU2089284900.SGD","IE00B775H168.HKD","LU2028103732.USD","BK4588","LU2471134952.CNY","LU1069344957.HKD","LU0943347566.SGD","IE00BFSS7M15.SGD","LU2602419157.SGD","LU0158827948.USD","LU1868836591.USD","IE00BJJMRX11.SGD","LU1868836757.USD","LU2357305700.SGD","02565","LU1093756325.SGD","LU1366192091.USD","LU2471134523.USD","SG9999017495.SGD","LU0122379950.USD","LU2756315318.SGD","LU0882574139.USD","LU0289739699.SGD","SGXZ99366536.SGD","IE00B1XK9C88.USD","LU2063271972.USD","BK4007","LU1629891620.HKD","LU0820561909.HKD","SG9999015986.USD","IE00BWXC8680.SGD","LU0354030438.USD","LU0417517546.SGD","IE0004445239.USD","BK4533","IE00BFSS8Q28.SGD","LU0708995401.HKD","LU1720051017.SGD","LU2111349929.HKD","LU2361045086.USD","LU0456855351.SGD","LU1814569148.SGD","LU2023250330.USD","LU2211815571.USD","LU2746668974.SGD","LU0787776722.HKD","IE0002141913.USD","LU2456880835.USD","LU2461242641.AUD","LU2756315664.SGD","LU0198837287.USD","IE00BJJMRY28.SGD","LU1064131342.USD","SG9999015978.USD","LU0106261372.USD","IE00BJT1NW94.SGD","LU0882574055.USD","SG9999018857.SGD","IE00B4R5TH58.HKD","LU0061475181.USD","LU0058720904.USD","LU0640476718.USD","LU1868836914.USD","LU1804176565.USD","LU2168564149.EUR","LU2552382058.USD","LU2552382132.HKD","LU0385154629.USD","LU1988902786.USD","LU0353189763.USD","SGXZ57979304.SGD","BK1161","LU0266013472.USD","LU0471298777.SGD","SG9999014898.SGD","IE0009355771.USD","LU1551013342.USD","LU0234572021.USD","LU0964807845.USD","LU1061106388.HKD","LU0320765992.SGD","LU1989771016.USD","LU0225283273.USD","SG9999014906.USD","LU2471134879.HKD","SG9999001176.SGD","IE00BJLML261.HKD","LU0320765059.SGD","LU2491050154.USD","IE0004445015.USD","LU1323610961.USD","LU0079474960.USD","LU2746668461.USD","SG9999015945.SGD","LU0203202063.USD","LU0210536198.USD","BK4585","LU0109391861.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1184100377","title":"PEGBIO CO-B (02565) Announces February 2026 Equity Update","url":"https://stock-news.laohu8.com/highlight/detail?id=1184100377","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184100377?lang=en_us&edition=fundamental","pubTime":"2026-03-04 17:47","pubTimestamp":1772617661,"startTime":"0","endTime":"0","summary":"PEGBIO CO-B (02565) reported no change in its registered share capital and issued shares for February 2026. The company’s total registered share capital remained at RMB 391.09 million, comprising...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":6,"totalSize":115,"code":"91000000","status":"200"}]}}